ANI Pharmaceuticals, Inc. (ANIP) on Decifer

Decifer ranks ANIP number 242 of 265 tracked names on durable business quality.

Why it ranks here

• Its returns on invested money are modest, around 6% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 44% a year, profits grew 437% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• It keeps issuing a lot of new shares, which dilutes its owners.
• 437 percent profit growth on 44 percent revenue growth is killed by 6 percent returns, dilution, no growth role, and 4 momentum capped below trend.

The current read

The evidence on ANIP lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Read the full ANIP research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.